DENV, March 22, 2018 -- The Global Down Syndrome Foundation applauds Congress for including funding for a new trans-National Institutes of Health (NIH) initiative to study Down syndrome in the final Fiscal Year 2018 Omnibus Appropriations legislation that is expected to pass this week. The provision, supported by the Global Down Syndrome Foundation, directs the NIH Director to lead a groundbreaking new scientific initiative to study immune system dysregulation and trisomy 21, with the aim of yielding research discoveries to improve the health of individuals with Down syndrome and typical individuals at risk for Alzheimer’s disease, cancer, cardiovascular disease, and autism, among others.
“Today’s action marks a significant advance in our efforts to improve the lives of individuals with Down syndrome as well as millions of other Americans,” said Michelle Sie Whitten, President, CEO, and Co-Founder of the Global Down Syndrome Foundation (Global). “We applaud our bipartisan allies in Congress especially the leadership of Appropriations Subcommittee Chairs Tom Cole (R-OK) and Senator Roy Blunt (R-MO) and Ranking Members Representative Rosa DeLauro (D-CT) and Senator Patty Murray (D-WA) as well as Representatives Cathy McMorris Rodgers (R-WA), Pete Sessions (R-TX), Mike Coffman (R-CO) and Cheri Bustos (D-IL).”
Last year, the Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, which provides federal funding for the NIH, held the first ever hearing on current and future research funding priorities for people with Down syndrome. The Subcommittee heard testimony from experts including Whitten, her colleague Dr. Joaquín M. Espinosa, Executive Director of the Linda Crnic Institute for Down Syndrome on the Anschutz Medical Campus, and Frank Stephens, a Global Quincy Jones Award Recipient and Advocate.
People who have three copies of chromosome 21 (instead of two) have Down syndrome, also known as trisomy 21. The additional copy of this small human chromosome leads to a radically different disease spectrum for people with Down syndrome whereby they are predisposed to or protected from major diseases that are the cause of death for over of 50% of Americans. For example, people with Down syndrome face an extraordinarily high prevalence of Alzheimer’s disease and a high prevalence of autoimmune disease and childhood leukemia. Conversely, they are protected against heart attack and solid cancers such as breast cancer or prostate cancer.
Recent, scientific research funded by Global and led by Dr. Espinosa, called the Crnic Institute Human TrisomeTM project, has led to a transformative discovery. Specifically, Dr. Espinosa’s lab found a continuous dysregulation of the immune system in all people with Down syndrome which may explain much of the different disease spectrum observed in this population. The new trans-NIH initiative – which will include the National Cancer Institute, the National Institute on Aging, and the National Institute for Child Health and Human Development – will help accelerate efforts to quickly build upon these findings and fuel new therapeutic discoveries that will improve the health of people with Down syndrome and millions of others.
Global is thrilled to know that its decade-long campaign to educate our government and invest in science has helped lead to this new development. Global looks forward to being a resource and working with the NIH as this initiative takes shape. This represents an amazing milestone for federal research on Down syndrome and our members and advocates join us in thanking Congress for making this a reality.
|
|||
###
About the Global Down Syndrome Foundation
The Global Down Syndrome Foundation is at the forefront of research, medical care, education and advocacy dedicated to significantly improving the lives of people with Down syndrome. Supporting the research of hundreds of scientists around the world, and through our advocates, partners and affiliates including the Crnic Institute for Down Syndrome and the Anna and John J. Sie Center for Down Syndrome, Global is making an impact on the lives of people with Down syndrome today, and remains focused on finding solutions tomorrow. We are committed to helping people with Down syndrome realize their fullest potential and to lead healthy and productive lives. To learn more, visit www.globaldownsyndrome.org.
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fdb4628c-8673-4bdf-af38-4a48c126aa94
Ed Mullen 202-329-4855 [email protected] Anca Elena Call Global Down Syndrome Foundation 720-320-3832 [email protected]


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Anta Sports Expands Global Footprint With Strategic Puma Stake
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



